Literature DB >> 1629630

Stereologic estimation of volume-weighted mean nuclear volume as a predictor of prognosis in "thin" malignant melanoma.

M Binder1, I Dolezal, K Wolff, H Pehamberger.   

Abstract

At present, tumor invasion represents the most reliable prognostic factor for primary malignant melanoma. The 10-year survival rate of "thin" melanomas (Breslow less than 0.76 mm) is more than 95%, but approximately 5% of these low-risk tumors do metastasize. In an attempt to determine prognostic markers for "thin" melanomas we investigated the volume-weighted mean nuclear volume (Vv) of primary melanomas with tumor invasions below 0.76 mm in 32 patients. Ten of these patients had developed melanoma metastases within a mean follow-up period of 49 months; 22 patients who had not developed metastases and who were comparable with regard to clinical and histologic criteria as well as to follow-up period were selected as a comparison group. Vv was determined by computer-assisted image analysis (IBAS 20, Kontron, Germany) on hematoxylin-eosin-stained sections employing stereologic estimation of the volume-weighted mean nuclear volume. In addition, two-dimensional morphometric parameters (nuclear area and shape factors) as well as clinical (sex, age, location) and histologic characteristics (Breslow's thickness, Clark's level, and growth patterns) were recorded. The mean Vv (+/- SD) of primary melanomas with subsequent metastatic course was 273 microns 3 (+/- 81.3), whereas primary melanoma lesions without subsequent metastases exhibited a significantly lower Vv of 154 microns 3 (+/- 25.3) (p = 0.0008). On the other hand, two-dimensional morphometric and clinical and histologic parameters did not correlate with prognosis. Vv thus seems to represent a powerful and independent prognostic marker for "thin" primary melanomas. Assessment of Vv may provide a valuable tool in selecting patients with high-risk stage I, Breslow less than 0.76 mm, melanoma for adjuvant therapy.

Entities:  

Mesh:

Year:  1992        PMID: 1629630     DOI: 10.1111/1523-1747.ep12616803

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

Review 1.  The use of design-based stereology to evaluate volumes and numbers in the liver: a review with practical guidelines.

Authors:  Ricardo Marcos; Rogério A F Monteiro; Eduardo Rocha
Journal:  J Anat       Date:  2012-02-01       Impact factor: 2.610

2.  Role of virus-specific CD4+ cytotoxic T cells in recovery from mouse hepatitis virus infection.

Authors:  O L Wijburg; M H Heemskerk; A Sanders; C J Boog; N Van Rooijen
Journal:  Immunology       Date:  1996-01       Impact factor: 7.397

3.  Anti-CD11b/CD18 antibodies reduce inflammation in acute colitis in rats.

Authors:  M J Palmen; C D Dijkstra; M B van der Ende; A S Peña; E P van Rees
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

4.  Effects of local budesonide treatment on the cell-mediated immune response in acute and relapsing colitis in rats.

Authors:  M J Palmen; L A Dieleman; M Soesatyo; A S Peña; S G Meuwissen; E P van Rees
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

5.  Non-lymphoid and lymphoid cells in acute, chronic and relapsing experimental colitis.

Authors:  M J Palmen; L A Dieleman; M B van der Ende; A Uyterlinde; A S Peña; S G Meuwissen; E P van Rees
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

6.  CD4+ T cells from 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis rodents migrate to the recipient's colon upon transfer; down-regulation by CD8+ T cells.

Authors:  M J Palmen; O L Wijburg; I H Kunst; H Kroes; E P van Rees
Journal:  Clin Exp Immunol       Date:  1998-05       Impact factor: 4.330

7.  Correlation between initial tumour volume and treatment duration on Dabrafenib: observation study of subjects with BRAF mutant melanoma on the BRF112680 trial.

Authors:  Arwa Ali; Monica Dumbrava; Kylie Riddell; Nina Stewart; Robyn Ward; Ahmed K Ibrahim; Melvin Chin
Journal:  BMC Cancer       Date:  2020-04-22       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.